Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors
Clinical Cancer Research, 07/03/2012
Cervantes A et al. – The recommended phase 2 dose of MLN8237 is 50mg BID on the 7–day schedule, which is being evaluated further in a variety of malignancies, including in a phase 3 trial in peripheral T–cell lymphoma.



